KẾT QUẢ ĐIỀU TRỊ BỆNH NHÂN UNG THƯ BUỒNG TRỨNG THỂ NHẦY GIAI ĐOẠN I-III TẠI BỆNH VIỆN K

Abstract

Objective: To describe the treatment outcomes of patients with mucinous ovarian carcinoma stage I–III at K Hospital. Methods: A retrospective combined with prospective descriptive study was conducted on 47 patients diagnosed histopathologically and treated at K Hospital during 2016–2024. Data were analyzed using descriptive statistics and the Kaplan–Meier method to estimate overall survival and disease-free survival, with group comparisons performed using appropriate statistical tests, and significance set at p < 0.05. Results: The mean overall survival (OS) was 71.6 ± 4.27 months, with 1-, 2-, and 5-year survival rates of 97.8%, 89.8%, and 81.2%, respectively. The mean disease-free survival (DFS) was 55.4 ± 5.06 months, with corresponding disease-free survival rates of 89.3%, 76.8%, and 53.3%. Analysis showed that OS differed significantly by FIGO stage (p = 0.02), with the best outcomes observed in stage I, while DFS differences across stages were not statistically significant (p = 0.91). Tumor size was strongly associated with DFS, as patients with tumors ≤ 15 cm had significantly better outcomes than those with tumors > 15 cm (p < 0.01), whereas OS did not differ significantly by tumor size (p = 0.47). Trends toward better prognosis were also observed in patients with expansile invasion compared to infiltrative patterns and in those with CA-125 < 35 U/ml compared to ≥ 35 U/ml, although these differences did not reach statistical significance. Conclusion: Disease stage is an important prognostic factor for overall survival, while tumor size plays a significant role in predicting disease-free survival. Both factors should be carefully considered for risk stratification, treatment decision-making, and long-term follow-up in patients with stage I–III MOC.